2024 World Conference on Lung Cancer (WCLC) - Posters-P2.07A.01 Clinicopathological vs. Molecular Models in Predicting Adjuvant EGFR-TKI Benefit in Stage I NSCLC

P2.07A.01 Clinicopathological vs. Molecular Models in Predicting Adjuvant EGFR-TKI Benefit in Stage I NSCLC

Pdf Summary

The study examines the effectiveness of clinicopathological versus molecular models in predicting the benefit of adjuvant epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with stage I non-small cell lung cancer (NSCLC) that have EGFR mutations. The focus is on determining which patients will gain the most from EGFR-TKI therapy post-surgery. <br /><br />The research, conducted between March 2013 and February 2019, evaluates the prognostic value of a 14-gene assay versus traditional clinicopathological factors. The primary measure of success was the 5-year disease-free survival (DFS) rate among patients. This study finds that the 14-gene assay is more effective than clinicopathological factors in predicting recurrence and assessing potential benefits from EGFR-TKIs.<br /><br />Specifically, the study identifies that patients categorized as molecular high-risk according to the 14-gene assay showed substantial benefits from adjuvant EGFR-TKIs, improving their DFS rates significantly (from 65.9% to 95.0% or 80.0% to 100%, depending on the subgroup). In contrast, molecular low-risk patients did not benefit from EGFR-TKIs, regardless of their clinicopathological risk status.<br /><br />This research highlights the importance of molecular profiling in deciding on adjuvant EGFR-TKI therapy for stage I NSCLC. It suggests that molecularly driven treatment decisions could lead to improved patient outcomes by targeting EGFR-TKIs to those most likely to benefit while avoiding unnecessary treatment in those less likely to respond. Such personalized treatment approaches can spare patients from unneeded interventions, optimizing the therapeutic regimen in early-stage lung cancer care. The study concludes that molecular profiling should play a pivotal role in guiding adjuvant EGFR-TKI decisions.

Asset Subtitle

Yu Jiang

Meta Tag

Speaker Yu Jiang

Topic Early-Stage NSCLC

Keywords

EGFR-TKI

NSCLC

molecular profiling

14-gene assay

clinicopathological factors

disease-free survival

adjuvant therapy

personalized treatment

lung cancer

EGFR mutations